DLL3 and neoplasm: Bispecific antibodies can attach to immune effector cells, such as NK cells or T-cells, and then direct them to tumor cells by binding both to immune cell receptors (e.g., CD3 on T-cells) and tumor-associated antigens (e.g., CD19 on B-cells or DLL3 on neuroendocrine tumors).